- Home
- SRFM vs SGMT Comparison
SRFM vs SGMT Comparison
Compare SRFM & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRFM | SGMT |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.7M | 164.6M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SRFM | SGMT |
|---|---|---|
| Price | $1.96 | $5.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $5.81 | ★ $27.00 |
| AVG Volume (30 Days) | ★ 1.8M | 691.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.66 | ★ 45.49 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,425,000.00 | $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.40 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 97.38 | N/A |
| 52 Week Low | $1.77 | $1.73 |
| 52 Week High | $9.35 | $11.41 |
Technical Indicators
Market Signals| Indicator | SRFM | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 48.98 |
| Support Level | $1.89 | $5.60 |
| Resistance Level | $2.10 | $6.72 |
| Average True Range (ATR) | 0.11 | 0.35 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 16.67 | 54.51 |
Price Performance
Historical ComparisonAbout SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.